Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasalfent versus immediate-release morphine for breakthrough cancer pain
NL-OMON31160Phase 3Not yet recruiting
- Sponsor
- i3 Research
- Start
- Mar 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of fentanyl and morphine in cancer pain (2 arms), sponsored by i3 Research. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
fentanylmorphine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NL-OMON31160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31160.